Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.

Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E.

Breast Cancer Res Treat. 2012 Nov;136(2):573-9. doi: 10.1007/s10549-012-2278-z. Epub 2012 Oct 6.

PMID:
23053662
2.

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P.

Br J Cancer. 2013 Sep 17;109(6):1522-7. doi: 10.1038/bjc.2013.499. Epub 2013 Sep 3.

3.

Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.

Kunovac Kallak T, Baumgart J, Stavreus Evers A, Sundström Poromaa I, Moby L, Kask K, Norjavaara E, Kushnir MM, Bergquist J, Nilsson K.

Climacteric. 2012 Oct;15(5):473-80. doi: 10.3109/13697137.2011.642427. Epub 2012 Feb 11.

PMID:
22324859
4.

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

Kyvernitakis I, Knöll D, Struck M, Hars O, Bauer T, Hadji P.

J Cancer Res Clin Oncol. 2014 Jan;140(1):159-66. doi: 10.1007/s00432-013-1557-3. Epub 2013 Nov 29.

PMID:
24292402
5.

Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.

Hubalek M, Oberguggenberger A, Beer B, Meraner V, Sztankay M, Oberacher H, Schubert B, Wildt L, Seeber B, Giesinger J, Kemmler G, Holzner B, Sperner-Unterweger B.

Clin Breast Cancer. 2014 Aug;14(4):291-6. doi: 10.1016/j.clbc.2013.12.008. Epub 2013 Dec 27.

PMID:
24468298
6.

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.

Lønning PE, Haynes BP, Dowsett M.

Eur J Cancer. 2014 Apr;50(6):1055-64. doi: 10.1016/j.ejca.2014.01.007. Epub 2014 Feb 4.

7.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
8.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
9.

Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.

Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wöckel A.

Breast Cancer Res Treat. 2012 Feb;131(3):925-31. doi: 10.1007/s10549-011-1874-7. Epub 2011 Nov 13.

PMID:
22080246
10.

Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.

Moegele M, Buchholz S, Seitz S, Ortmann O.

Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. Review.

PMID:
22212649
11.

Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.

Elliott KM, Dent J, Stanczyk FZ, Woodley L, Coombes RC, Purohit A, Palmieri C.

Br J Surg. 2014 Jul;101(8):939-48. doi: 10.1002/bjs.9477. Epub 2014 Mar 31.

PMID:
24687409
12.

Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: reversible effect of weight loss.

Enriori CL, Orsini W, del Carmen Cremona M, Etkin AE, Cardillo LR, Reforzo-Membrives J.

Gynecol Oncol. 1986 Jan;23(1):77-86.

PMID:
3943755
13.

Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.

Geisler J, Haynes B, Ekse D, Dowsett M, Lønning PE.

J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):27-34. Epub 2007 Mar 9.

PMID:
17350249
14.

Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.

Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S.

Steroids. 2007 Jul;72(8):666-71. Epub 2007 May 21.

PMID:
17588628
15.

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL.

J Clin Oncol. 2007 Sep 1;25(25):3877-83.

PMID:
17761973
16.

Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.

Crew KD, Capodice JL, Greenlee H, Apollo A, Jacobson JS, Raptis G, Blozie K, Sierra A, Hershman DL.

J Cancer Surviv. 2007 Dec;1(4):283-91. doi: 10.1007/s11764-007-0034-x. Epub 2007 Oct 12.

PMID:
18648963
17.

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.

van Londen GJ, Perera S, Vujevich K, Rastogi P, Lembersky B, Brufsky A, Vogel V, Greenspan SL.

Breast Cancer Res Treat. 2011 Jan;125(2):441-6. doi: 10.1007/s10549-010-1223-2. Epub 2010 Nov 3.

18.

Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ.

Eur J Cancer. 2015 Sep;51(14):1890-6. doi: 10.1016/j.ejca.2015.06.113. Epub 2015 Jul 10.

PMID:
26169018
19.

Obesity and nonadherence correlate with elevated serum estradiol levels in postmenopausal women receiving adjuvant aromatase inhibitor therapy.

Decker DA, Reynolds RB, Molthrop DC, Griffith E, Encarnacion T, Lee E, Zhu X.

Breast J. 2014 Sep-Oct;20(5):553-4. doi: 10.1111/tbj.12324. Epub 2014 Aug 2. No abstract available.

PMID:
25088121
20.

Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.

Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M, Coleman R.

Cancer Treat Rev. 2011 Apr;37(2):97-104. doi: 10.1016/j.ctrv.2010.05.005. Epub 2010 Jul 1. Review.

PMID:
20594763

Supplemental Content

Support Center